Precision BioSciences
DTIL
65 hedge funds and large institutions have $13M invested in Precision BioSciences in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 15 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
10% more capital invested
Capital invested by funds: $11.8M → $13M (+$1.14M)
0.03% less ownership
Funds ownership: 1% → 0.97% (-0.03%)
14% less funds holding
Funds holding: 76 → 65 (-11)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.22M |
| 2 |
Renaissance Technologies
New York
|
+$359K |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
+$218K |
| 4 |
Two Sigma Advisers
New York
|
+$180K |
| 5 |
Morgan Stanley
New York
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$573K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$486K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$395K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$140K |
| 5 |
JP Morgan Chase
New York
|
-$61.2K |
DTIL Hedge Fund Activity: Q4 2023 in Review
65 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q4 2023, worth a combined $13M — up 9.7% from $11.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of DTIL and 8 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 21 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $1.22M. The largest seller was Capital World Investors, cutting an estimated $573K.
- 65 institutional investors held Precision BioSciences (DTIL) as of Q4 2023, down from 76 in Q3 2023.
- Funds reported $13M of Precision BioSciences stock for Q4 2023, up 9.7% quarter-over-quarter.
- 8 funds opened new Precision BioSciences positions in Q4 2023 and 15 closed out, a net change of -7 holders.
- The largest Precision BioSciences buyer in Q4 2023 was Tang Capital Management, an estimated $1.22M added.
- The largest Precision BioSciences seller in Q4 2023 was Capital World Investors, an estimated $573K sold.
Based on aggregated 13F filings for Q4 2023.